X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.
Lead Product(s): A166
Therapeutic Area: Oncology Product Name: A166
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Levena Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".
Lead Product(s): Macromolecule-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,407.0 million Upfront Cash: $47.0 million
Deal Type: Licensing Agreement May 16, 2022
Details:
A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.
Lead Product(s): A166
Therapeutic Area: Oncology Product Name: A166
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Levena Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
